Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Mild to Moderate Diabetic Sensorimotor Polyneuropathy

In brief

The purpose of this study is to determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy.

Key facts

Study ID
NCT00927914
Run by
Eisai Inc.
People needed
800
Starts
2009-07-01
Expected to finish
2013-02-01
Last updated by the study team
2019-02-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.